Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy-Reference-Cited by-同舟云学术

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Published:2013-05-07 Issue:5 Volume:19 Page:691-697
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Lentz S. R.¹,Misgav M.²,Ozelo M.³,Šalek S. Z.⁴,Veljkovic D.⁵,Recht M.⁶,Cerqueira M.⁷,Tiede A.⁸,Brand B.⁹,Mancuso M. E.¹⁰,Seremetis S.¹¹,Lindblom A.¹²,Martinowitz U.²

Affiliation:

1. Department of Internal Medicine; The University of Iowa Carver College of Medicine; Iowa City; IA; USA

2. National Hemophilia Center; Chaim Sheba Medical Center Affiliated to the Sackler School of Medicine; Tel Aviv University; Tel Aviv; Israel

3. IHTC ‘Claudio L. P. Correa’; INCT do Sangue Hemocentro UNICAMP; University of Campinas; Sao Paulo; Brazil

4. National Referral Haemophilia and Thrombophilia Centre; University Hospital Centre; Zagreb; Croatia

5. Transfusion Medicine Department; Institute for Mother and Child Health Care of Serbia; Belgrade; Serbia

6. The Hemophilia Center; Oregon Health & Science University; Portland; OR; USA

7. HEMORIO; Rio de Janeiro; Brazil

8. Medizinische Hochschule Hannover; Hannover; Germany

9. Division of Hematology; University Hospital; Zürich; Switzerland

10. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; Fondazione IRCCS Ca' Granda; Ospedale Maggiore Policlinico; Milan; Italy

11. Haemophilia R&D Portfolio; Novo Nordisk Inc.; Princeton; NJ; USA

12. Medical & Science Haemophilia; Novo Nordisk A/S; Soeborg; Denmark

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12159/fullpdf

Reference17 articles.

1. Practice patterns in haemophilia A therapy - global progress towards optimal care;Geraghty;Haemophilia,2006

2. Purification and characterization of a new recombinant factor VIII (N8);Thim;Haemophilia,2010

3. Functional characteristics of N8, a new recombinant FVIII;Christiansen;Haemophilia,2010

4. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and Advate®)-an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A;Martinowitz;Haemophilia,2011

5. International comparative field study of N8 evaluating factor VIII assay performance;Viuff;Haemophilia,2011

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous Infusion of Turoctocog Alfa in Patients With Mild to Moderate Hemophilia A: A Case Series;American Journal of Therapeutics;2024-07-11

2. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII;Acta Haematologica;2024-04-23

3. Defining success in haemophilia care – Are we doing it right?;Haemophilia;2024-03-18

4. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study;Hematology;2024-02-20

5. Efficacy and safety of turoctocog alfa in patients with hemophilia A requiring surgical procedures: A multicentre retrospective study;Transfusion;2023-10-18